Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
91% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. GALT: No Debt )
GALT' s 10-Year Cash to Debt Range
Min: 1.59   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
79% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. GALT: No Debt )
GALT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -0.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -79.03
GALT's ROE (%) is ranked higher than
50% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. GALT: -79.03 )
GALT' s 10-Year ROE (%) Range
Min: -913.68   Max: -81
Current: -79.03

-913.68
-81
ROA (%) -55.12
GALT's ROA (%) is ranked higher than
50% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. GALT: -55.12 )
GALT' s 10-Year ROA (%) Range
Min: -1309.12   Max: -56.38
Current: -55.12

-1309.12
-56.38
ROC (Joel Greenblatt) (%) -771500.00
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. GALT: -771500.00 )
GALT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -771500   Max: -3076.64
Current: -771500

-771500
-3076.64
EBITDA Growth (3Y)(%) -2.60
GALT's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. GALT: -2.60 )
GALT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 11.5
Current: -2.6

0
11.5
EPS Growth (3Y)(%) -100.00
GALT's EPS Growth (3Y)(%) is ranked higher than
67% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. GALT: -100.00 )
GALT' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 35.1
Current: -100

-100
35.1
» GALT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

Q1 2014

GALT Guru Trades in Q1 2014

George Soros 48,200 sh (New)
» More
Q2 2014

GALT Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
GALT's P/B is ranked higher than
68% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. GALT: 3.50 )
GALT' s 10-Year P/B Range
Min: 0   Max: 457.5
Current: 3.5

0
457.5
EV-to-EBIT -3.55
GALT's EV-to-EBIT is ranked higher than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. GALT: -3.55 )
GALT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.55

Current Ratio 17.42
GALT's Current Ratio is ranked higher than
98% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. GALT: 17.42 )
GALT' s 10-Year Current Ratio Range
Min: 0.29   Max: 20.36
Current: 17.42

0.29
20.36
Quick Ratio 17.42
GALT's Quick Ratio is ranked higher than
98% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. GALT: 17.42 )
GALT' s 10-Year Quick Ratio Range
Min: 0.29   Max: 20.36
Current: 17.42

0.29
20.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
GALT's Price/Net Cash is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. GALT: 3.00 )
GALT' s 10-Year Price/Net Cash Range
Min: 7.04   Max: 115.43
Current: 3

7.04
115.43
Price/Net Current Asset Value 3.10
GALT's Price/Net Current Asset Value is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. GALT: 3.10 )
GALT' s 10-Year Price/Net Current Asset Value Range
Min: 6.94   Max: 161.6
Current: 3.1

6.94
161.6
Price/Tangible Book 3.60
GALT's Price/Tangible Book is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. GALT: 3.60 )
GALT' s 10-Year Price/Tangible Book Range
Min: 4.87   Max: 516
Current: 3.6

4.87
516
Price/DCF (Projected) 8.40
GALT's Price/DCF (Projected) is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. GALT: 8.40 )
GALT' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 8.4

Earnings Yield (Greenblatt) -29.70
GALT's Earnings Yield (Greenblatt) is ranked lower than
56% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. GALT: -29.70 )
GALT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.2   Max: 0
Current: -29.7

-36.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PHPN.Germany,
Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for GALT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
GALECTIN THERAPEUTICS INC Financials Mar 25 2015
Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of... Mar 24 2015
Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of... Mar 24 2015
Galectin Therapeutics reports 4Q loss Mar 18 2015
Galectin Therapeutics reports 4Q loss Mar 18 2015
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update Mar 18 2015
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update Mar 18 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 18 2015
The Shuman Law Firm Investigates Galectin Therapeutics, Inc. Mar 17 2015
Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special... Mar 12 2015
Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special... Mar 12 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 12 2015
Galectin Therapeutics to Present at the 27th Annual ROTH Conference Mar 02 2015
Galectin Therapeutics to Present at the 27th Annual ROTH Conference Mar 02 2015
Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 Feb 24 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 24 2015
Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 Feb 24 2015
RedChip Announces Presentation Schedule for Its January 28-29 Online Investor Conference Jan 21 2015
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for... Jan 07 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK